Mylod%2525252525252525252525252525252525252525252525252525252520at

## Mylot%25252525252525252525252525252525252525252525252525252525at ### Overview Mylot%25252525252525252525252525252525252525252525252525252525at is a combination medication containing **[List active ingredients here and their strengths, e.g., Lidocaine 2.5% and Prilocaine 2.5%]**. It is a topical anesthetic. ### Primary Indications * **Topical anesthesia** for superficial procedures such as needle insertion (e.g., IV cannulation, blood sampling) and minor superficial surgery (e.g., split-thickness skin grafting). ### Adult Dosing * **Topical anesthesia:** Apply a thick layer to intact skin and cover with an occlusive dressing. * **For needle insertion:** Apply for at least 60 minutes. * **For minor superficial surgery:** Apply for 2-5 hours. * The **maximum application area and total dose** will depend on the specific procedure and formulation used. Refer to the manufacturer's labeling for precise guidelines. ### Pediatric Dosing * **Neonates and infants (up to 12 months):** Maximum application area is 10 cm$^2$. Maximum total dose is 1 gram. Apply for no longer than 1 hour. * **Children (1-12 years):** * Maximum application area is 100 cm$^2$ (e.g., 10 cm x 10 cm). * Apply for 1-2 hours depending on the procedure. * **Adolescents (12 years and older):** Dosing is generally the same as adults, but caution is advised regarding total dose and application area. * **Specific dosing for pediatric patients may vary based on weight and the procedure being performed.** Consult specific pediatric guidelines or the manufacturer's product information. ### Dose Adjustments * **Renal Impairment:** Use with caution; consider reduced doses or increased monitoring, especially in severe impairment. * **Hepatic Impairment:** Use with caution; consider reduced doses or increased monitoring, especially in severe impairment. ### Contraindications * Hypersensitivity to lidocaine, prilocaine, amide-type anesthetics, or any component of the formulation. * Avoid application to mucous membranes or damaged/irritated skin. * Application to large areas in infants under 12 months due to risk of methemoglobinemia. ### Adverse Effects * **Common:** Skin reactions at the application site (erythema, pallor, edema, burning, itching). * **Rare but serious:** * **Methemoglobinemia:** Particularly in infants and in cases of overdose or prolonged application. * Allergic reactions (anaphylaxis). * Systemic toxicity if absorbed in significant amounts (CNS effects like dizziness, seizures; cardiovascular effects like bradycardia, hypotension). ### Key Drug Interactions * **Methemoglobinemia-inducing agents:** Increased risk of methemoglobinemia when used concurrently with drugs such as sulfonamides, nitrofurantoin, and antimalarials. * **Class I antiarrhythmics (e.g., lidocaine, tocainide, mexiletine):** Potential for additive effects if systemic absorption occurs. * **CYP1A2 and CYP3A4 substrates:** Prilocaine is metabolized by these enzymes; significant interactions are not typically expected with topical use at recommended doses, but caution may be warranted with very large applications or in patients with impaired metabolism. ### Monitoring * **Skin reaction** at the application site. * **Signs and symptoms of methemoglobinemia** (cyanosis, headache, dizziness, fatigue, shortness of breath) especially in pediatric patients or with extensive application. * **Signs of systemic toxicity** if overdose is suspected. ### Clinical Pearls * Ensure the correct application duration and area are followed to minimize systemic absorption and the risk of adverse effects, especially methemoglobinemia. * Occlusive dressings are crucial for effective anesthesia but also increase the rate of absorption. * Allow adequate time for the anesthetic to take effect before the procedure. * The effectiveness and safety in neonates require careful consideration and adherence to strict dosing guidelines. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before administering any medication. Patient-specific factors may alter recommendations.